News

Sanochemia: US-Partner Avigen commences multicentric phase II study in the development programme for tolper...

Sanochemia: US-Partner Avigen commences multicentric phase II study in the development programme for tolperisone

Boehringer Ingelheim to initiate first Phase III pivotal study for new oncology compound BIBW 2982

Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to…

Sanochemia: Nine-Months-Report 2007 published

(1.10.2006 – 30.6.2007)

- Forecast increase in sales revenues of 5%
- Marked improvement in operating performance
- All…

Sanochemia Partner Avigen, Inc. reports successful completion of two key clinical trials in the development...

Sanochemia Partner Avigen, Inc. reports successful completion of two key clinical trials in the development programme…

Intercell's therapeutic HCV vaccine meets primary endpoints in Phase II interim analysis

» First data from 25 patients reveals statistically significant viral load reduction and very good safety profile
» Data…

Sanochemia files Scanlux in US

The Austrian public pharmaceutical company, Sanochemia Pharmazeutika AG, whose shares are traded in the Prime Segment of…

Nabriva: Initiation of Clinical Phase I Study of Topical Antibiotic

Nabriva Therapeutics announced today commencement of a clinical phase I program for its topical pleuromutilin antibiotic…

Intercell announces Q2 2007 Results

Intercell AG announces Q2/ H1 results and gives update on business:

Full year 2007 expected to be profitable All…

Ad-hoc-Announcement according to §15 WpHG Sanochemia Pharmazeutika AG - WKN919963

Ad-hoc-Announcement according to §15 WpHG Sanochemia Pharmazeutika AG - WKN919963 New and surprising research results…

Affiris begins clinical testing of Alzheimer's vaccine

The Alzheimer’s vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All…

First child vaccinated with Intercell JE Vaccine in India - Pediatric Phase II trial started

» Development process for vaccine launch in endemic countries accelerated – First child vaccinated with IC51
» First…

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.